复合式冷热消融系统治疗肿瘤的Mini-卫生技术评估

Health Technology Assessment of A New Generation of Domestic Co-ablation System

目的 对复合式冷热消融系统治疗肿瘤患者进行Mini-卫生技术评估(Mini-HTA),为该类设备的精细化配置提供循证证据,为Mini-HTA在医院的实际应用提供参考。方法 利用Mini-HTA方法,通过文献调研、专家咨询等方式,从技术特性、安全性、有效性、经济性和社会影响等方面对复合式冷热消融系统进行技术评估。结果 复合式冷热消融技术原理具有创新性;治疗肺癌、胰腺癌安全性较好,无严重不良反应;与单纯冷冻消融相比,其治疗非小细胞肺癌疗效具有非劣性,治疗胰头癌患者生存率更高;投资回收期为2.2年,经济效益好;相比于外科手术和三维适型放疗等方式,患者住院天数少,住院费用低。结论 复合式冷热消融技术的引进可实现肿瘤消融技术升级,有助于降低平均住院时间和减轻患者经济压力,设备投资收益可观,具有配置价值。

Objective We aimed to evaluate the technology of the new generation of domestic co-ablation system and provide evidence-based evidence for the fine configuration of this kind of equipment. Methods Mini-Health Technology Assessment(HTA)template was used to evaluate the configuration of a new generation of domestic co-ablation system by literature research and expert consultation from technical, patient, hospital and economic level. Results The technology of co-ablation is innovative;It is safe in the treatment of lung and pancreatic cancer without serious complications.Co-ablation is noninferior to argon-helium cryoablation in terms of efficacy and safety for the treatment of non-small cell lung cancer. Compared with argon-helium cryoablation, the patients with pancreatic head cancer who received co-ablation has a better survival rate.According to the forecast of 250 cases per year, the payback period of investment is 2.2 years.The average length of hospital stay and total cost of co-ablation are lower than traditional surgery and three-dimensional appropriate radiotherapy. Conclusion The evaluation results show that the introduction of this technology can realize the upgrading of tumor ablation technology, help to reduce the average length of hospital stay and relieve the economic pressure of patients, and the equipment investment returns are considerable, which has configuration value.